Novavax ( NVAX ) last month reported a delay in its plan to seek clearance for its coronavirus vaccine candidate to the third quarter, which starts in September. Delays in clinical-trial results coupled with manufacturing delays had slowed the process by which the company would seek Food and Drug Administration clearance, people briefed on the matter told the Washington Post. Jim Cramer said he doesn't like Novavax because they are having problems making it at scale.